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DATA NOTE
Quality of life of colorectal cancer survivors 
in a Ghanaian population
Joseph Yorke2, Emmanuel Acheampong1,3* , Emmanuella Nsenbah Batu1, Christian Obirikorang1, 
Francis Agyemang Yeboah1 and Evans Adu Asamoah1
Abstract 
Objective: We collected data to evaluate the quality of life of patients who have survived between one and 8 years 
from the diagnosis of colorectal cancer.
Data description: We collected quality of life (QoL) data from colorectal patients who were diagnosed between 
2009 and 2015 at the Komfo Anokye Teaching Hospital (KATH) and have survived until January 2017. The dataset 
consists of patients’ demographic data, clinicopathological characteristics, and QoL data. The validated QoL instru-
ments for data curation was an adopted version of the European Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30 and the EORTC QLQ-CR29. The QLQ-C30 was a 30-item general cancer instrument with 5 functional 
subscales, and 9 symptom subscales, whereas the QLQ-CR29 was a 29-item scale that consisted of 3 functional QOL 
subscales and 14 symptom subscales, that are associated with colorectal cancer and its treatment. The QoL instru-
ment was coded such that higher scores indicated increased function and better QoL, and higher symptom scores 
represent worse symptoms.
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Objective
Colorectal cancer (CRC) from the global perspective is 
the third most common malignant neoplasm but was 
considered to be rare within the African context [1, 2]. 
However, recent accumulating evidence has shown that 
numerous African countries which were traditionally 
recognized as low-risk countries [3, 4] including Ghana 
[5], has reportedly increased the rate of CRC. These 
trend has previously been confirmed in our previous 
work [6] at a major teaching hospital in Ghana. CRC in 
these countries represents about 10–50% of all malignant 
tumours and has a characteristic unique pattern with an 
early age of onset and mostly left-sided tumours [6, 7].
Whereas an increase in survival rates is clearly a great 
accomplishment, there are unintended negative con-
sequences with treatments that can potentially reduce 
the QoL [8, 9]. Colorectal cancer patients may suffer 
long-lasting pain and reductions in functional and social 
well-being irrespectively of the type of treatment includ-
ing surgery, radiation therapy, and systemic chemo-and 
targeted therapy [10]. Therefore, we explored the extent 
to which health-related quality of life is affected by CRC 
and identified key areas that merit further attention to 
improve the quality of survival after CRC is being diag-
nosed and treated. These effects are explored through 
the analysis of survey questions answered by survivors of 
colorectal cancer relating to their QoL. The current data 
on QoL in CRC patients may improve our understand-
ing of how cancer and its therapy influence the patients’ 
lives, and how to adapt appropriate treatment strategies. 
Part of the results based on this data has been published 
in PLOS ONE [11].
Data description
We did our data collection in two parts. First, we did a 
retrospective review of the case files of all CRC patients 
diagnosed and managed at KATH from 2009 to 2015 
and have survived till January 2017, from the Medical 
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Department. We analyzed for information on demo-
graphics, clinical and pathological variables including 
histological type, grade of tumour and staging based on 
the TNM. The type of treatment and follow-up were 
also analyzed. Information on age at diagnosis, gender, 
tumour location, pathological type of tumour, treatment 
modality, family history of CRC, and metastasis were also 
reviewed, and the dataset is shown in Table 1. Secondary, 
all patients whose information was reviewed were con-
tacted through phone calls, their identity confirmed with 
age, name, and hospital identification number and visited 
by the research team for interview. In total, 220 cases 
were confirmed and included after obtaining their verbal 
and written informed consent to partake in the study.
The instrument used to assess QoL in this study were 
the European Organization for Research and Treatment 
of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-
CR29. The QLQ-C30 was an overall cancer instrument 
which contains a 30-items that assess global QOL; 5 
functional subscales (emotional, cognitive, social, and 
physical role), and 9 symptom subscales (nausea/vomit-
ing, fatigue, appetite loss, diarrhoea, sleep disturbance, 
pain and financial influence) [12]. The EORTC QLQ-
CR29 consist 29-items that assess three functional QOL 
items (weight anxiety and body image) and (14) symptom 
items (mucus and blood in stool, frequency of urination 
and stool, dysuria, pain in the abdomen and buttock, feel-
ing bloated, urinary and faecal incontinence, bloated feel-
ing, dry mouth, loss of hair, trouble with taste, sore skin, 
and flatulence) that are related to CRC and its treatment 
[13]. For both QLQ-C30 and QLQ-CR29, the responses 
were scored on a Likert scale of 4 response categories. 
Higher functional and global QoL domain scores indi-
cated increased function and better QoL, and a higher 
symptom score represents worse symptoms. The data-
set for responses to QLQ-C30 and QLQ-CR29 has been 
shown in Table 1.
Limitations
The data reflect specific patient population reporting to 
KATH. Thus, making it an institutional-based study but 
not a population-based study. Also, we assumed, those 
who die before a year are likely to have more advanced 
disease and more co-morbidities than those who survive 
and are likely to report low QoL, however, our data did 
not capture such patients. No information was available 
from respondents on their QoL prior to being diagnosed 
with CRC. In the same way, there was no information 
available for non-cancer controls of age, sex and socio-
economic status matched population, which is consid-
ered a major limitation of the study.
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Table 1 Overview of data files/data sets
Label Name of data file/data set File types
(file extension)
Data repository and identifier (DOI 
or accession number)
Data file 1 Table for comparison of QOL based on primary 
cancer site
MS Excel file (.xlsx) https ://doi.org/10.6084/m9.figsh are.99586 73.v1
Data set 1 Colorectal cancer data set (Quality of life) MS Excel file (.xlsx) https ://doi.org/10.6084/m9.figsh are.99586 70.v4
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